CA
NZ
UK
AU
IND
US
Arshia Sarkhani, Chief Marketing Officer and Director at Strive, Inc., was reported as acquiring 9,191 Performance Stock Units tied to Class A Common Stock on August 7, 2026, according to a beneficial ownership statement filed with the SEC on August 10, 2026.
Dole plc filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on August 10, 2026, covering the quarterly period ended June 30, 2026.
JBG SMITH Properties filed its quarterly report on Form 10-Q with the SEC on August 10, 2026, covering the quarter and six months ended June 30, 2026, disclosing a net loss attributable to common shareholders of $59.2 million for the second quarter and $77.9 …
Strive, Inc. filed its Form 10-Q for the quarterly period ended June 30, 2026 with the U.S. Securities and Exchange Commission on August 10, 2026, reporting a net loss of $523.5 million for the six months ended June 30, 2026.
Strive, Inc. filed a Current Report on Form 8-K with the SEC on August 10, 2026, disclosing that it issued a press release announcing its financial results for the quarter ended June 30, 2026.
Freedom Holding Corp. filed its Form 10-Q for the quarterly period ended June 30, 2026 with the U.S. Securities and Exchange Commission, reporting net income of $31,660 thousand and total assets of $14,046,883 thousand for the three months ended June 30, 2026.
Silence Therapeutics plc (Nasdaq: SLN), a clinical-stage RNA medicine company incorporated in England and Wales, filed its quarterly report on Form 10-Q for the period ended June 30, 2026, with the U.S. Securities and Exchange Commission on August 10, 2026.
OPAL Fuels Inc. filed a current report on August 10, 2026, disclosing the issuance of a press release covering its financial results for the quarter ended June 30, 2026.
Jade Biosciences, Inc. filed its quarterly report on Form 10-Q for the period ended June 30, 2026, with the Securities and Exchange Commission on August 10, 2026, disclosing a net loss of $96.1 million for the first half of the year and total assets …
Silence Therapeutics plc filed a current report on August 10, 2026, disclosing positive topline results from the Phase 2 SANRECO trial evaluating divesiran in polycythemia vera.
Please wait processing your request...